Asset Details
Do you wish to reserve the book?
Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion
Do you wish to request the book?
Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion
2025
Overview
Donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (alloSCT) can boost Graft-versus-Leukaemia (GvL) reactivity but may induce Graft-versus-Host-Disease (GvHD). It is essential to understand which factors besides timing, donor type, and dose influence DLI alloreactivity. We previously identified viral infections, ≥ 5% patient cells in bone marrow chimerism, and lymphopenia at the time of DLI as relevant factors for GvHD after DLI following alemtuzumab-based T-cell depletion. Here, we investigated these factors and the alloreactivity after DLI following alloSCT with posttransplant cyclophosphamide in 83 patients with acute leukaemia/myelodysplastic syndrome receiving a prophylactic or preemptive DLI. 5% had viral infections close to DLI, 6% had ≥ 5% mixed chimerism, and 17% had lymphopenia. 2-year cumulative incidence of GvHD requiring systemic treatment was low: 7% (95%-confidence interval 1–14%). 22 of the 28 patients with ≥ 1% mixed chimerism at the time of DLI (79%) converted to full-donor chimerism. None of these responders relapsed, indicating achievement of GvL despite the low incidence of GvHD. Our data show that DLI alloreactivity is determined by the conditions at the time of DLI which are influenced by the transplantation strategy. Adjusting the DLI dose based on these conditions may improve the balance between GvHD and GvL.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Female
/ Graft vs Host Disease - epidemiology
/ Graft vs Host Disease - etiology
/ Graft vs Host Disease - prevention & control
/ Hematopoietic Stem Cell Transplantation - adverse effects
/ Hematopoietic Stem Cell Transplantation - methods
/ Humans
/ Leukemia
/ Lymphocyte Transfusion - adverse effects
/ Lymphocyte Transfusion - methods
/ Male
/ Medicine
/ Myelodysplastic Syndromes - therapy
/ Oncology
/ Patients
